Received by email:

File: News Release - PP for Communications 10.26.17.pdf

890 West Pender Street, Suite 600                                    69 Longwood Avenue
Vancouver, British Columbia                                          Hyannis Port, MA,02647 USA
Canada V6C 1J9                                                       617-571-6006
778-998-5000                                                         www.imaginmedical.com

CSE Symbol: IME                                                      NR-2017-IME - 17
OTC Pink Symbol: IMEXF
Frankfurt/Stuttgart Stock Exchange: DPD2


                          IMAGIN MEDICAL CLOSING FINANCING
                        TO BROADEN COMMUNICATIONS PROGRAM

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will
establish a new standard of care for urologists in detecting cancers and visualizing the
surgical field in minimally invasive surgery. The Company's initial focus is bladder cancer.
______________________________________________________________________

Vancouver, B.C. and Boston, MA, October 26, 2017   Imagin Medical, Inc. (CSE: IME)
(OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the "Company")
announces it is closing a $120,000 financing to raise funds to be used for the Company's
communications program (the "Financing"). This financing will not be oversubscribed.
The Company is committed to continuing the development of the i/Blue Imaging System
for the detection of bladder cancer and keeping its shareholders informed of its progress.

The funds raised pursuant to the Financing will be specifically targeted for a
communications and marketing program, allowing the Company to continue to maintain
its existing cash for product development and commercialization. The Financing will
consist of 800,000 units (the "Units") at a price of $0.15 per Unit, each Unit to be
comprised of one common share and one half of one common share purchase warrant
(the "Warrants"). Each whole Warrant will be exercisable into one common share in the
equity of the Company (the "Warrant Shares") at an exercise price of $0.25 per Warrant
Share. The Warrants expire one year from date of issuance.

About Imagin Medical
Imagin Medical is developing imaging solutions for minimally invasive surgical procedures
where endoscopes are used. The Company believes it will radically improve the way
physicians detect cancer and view the surgical field. Imagin's initial target market is
bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the
most costly cancer to treat due to a greater than 50% recurrence rate. The ultrasensitive
imaging technology is based upon improved optical designs and advanced light sensors.
Learn more at www.imaginmedical.com


For further information, contact:
Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: jhutchens@imaginmedical.com

{00858280;1}
 Information set forth in this news release contains forward-looking statements. These statements reflect
management's current estimates, beliefs, intentions and expectations; they are not guarantees of future
performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual
performance may be affected by a number of material factors, many of which are beyond the Company's control.
Accordingly, actual and future events, conditions, and results may differ materially from the estimates, beliefs,
intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no
assurance the Company's imaging system will work in the manner expected, except as required under applicable
securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking
information. The CSE has neither approved nor disapproved the information contained herein and does not accept
responsibility for the adequacy or accuracy of this news release.




{00858280;1}